<DOC>
	<DOC>NCT02334306</DOC>
	<brief_summary>A Phase 2a study to evaluate the efficacy and safety of AMG 557/MEDI5872 in Primary Sjögren's Syndrome</brief_summary>
	<brief_title>A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome</brief_title>
	<detailed_description>This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the clinical and biologic efficacy, as well as the safety of SC doses of AMG 557/MEDI5872 in adult subjects with Primary Sjögren's Syndrome.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<criteria>Age 18 through 75 years at the time of signing the ICF. Fulfill AmericanEuropean Consensus Group (AECG) criteria for pSS ESSDAI score ≥ 6. Positive antiSSA and/or antiSSB autoantibodies and at least IgG &gt; 13 g/L or RF level &gt; upper limit of normal (ULN) or positive test for cryoglobulins Willingness to undergo protocolrequired minor salivary gland biopsies. Negative TB test during screening Immunization up to date as determined by local standard of care. Previous treatment with AMG 557/MEDI5872. Evidence of signs or symptoms of a viral, bacterial, or fungal infection within 2 weeks (14 days) prior to randomization (Day 1) according to the assessment of the investigator; any infection requiring IV antibiotic or antiviral treatment within 8 weeks of randomization (Day 1); history of herpes zoster within 3 months prior to randomization (Day 1). Evidence of significant renal insufficiency Positive test at screening for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) antibody. Prior administration of any of the following: 1. Belimumab in the past 6 months prior to randomization (Day 1); 2. Rituximab in the past 12 months or CD19+ B cells &lt; 5/µL if rituximab treatment was more than 12 months prior to randomization (Day 1); 3. Abatacept in the past 6 months prior to randomization (Day 1); 4. Tumor necrosis factor inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) in the past 3 months prior to randomization (Day 1); 5. Tocilizumab in the past 3 months prior to randomization (Day 1); 6. Cyclophosphamide (or any other alkylating agent) in the past 6 months prior to randomization (Day 1); cyclosporine (except for eye drops), tacrolimus, sirolimus, mycophenolate mofetil, azathioprine, or leflunomide in the past 3 months prior to randomization (Day 1). Receiving any of the following: 1. Corticosteroids: &gt; 10 mg/day oral prednisone (or equivalent); Any change or initiation of new dose within 4 weeks prior to signing the ICF through randomization (Day 1); Intramuscular, IV, or intraarticular corticosteroids within 4 weeks prior to signing the ICF through randomization (Day 1); Any change or initiation of new dose of topical corticosteroids within 2 weeks prior to signing the ICF through randomization (Day 1); 2. Antimalarials: any increase or initiation of new dose of antimalarials (eg, chloroquine, hydroxychloroquine, quinacrine) within 12 weeks prior to signing the ICF through randomization (Day 1). 3. Methotrexate: &gt; 20 mg/week methotrexate; Any change or initiation of new dose of methotrexate within 4 weeks prior to signing the ICF through randomization (Day 1); Any change in route of administration. 4. Any increase or initiation of new dose of regularly scheduled nonsteroidal anti inflammatory drugs (NSAIDs) within 2 weeks prior to signing the ICF through randomization (Day 1). 5. Cevimeline or pilocarpine and cyclosporine eye drops (Restasis): any increase or initiation of new doses within 2 weeks prior to signing the ICF through randomization (Day 1).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>